LDL-C level reduction <25 mg/dL with alirocumab not tied to MACE reduction: Circulation Medha Baranwal29 Jan 2021 9:27 PM ISTUSA: Acute coronary syndrome (ACS) patients treated with alirocumab who achieved LDL-C levels <25 mg/dL versus 25–50 mg/d did not show any...
Sanofi, Regeneron win EU patent case against Amgen over Praluent Ruchika Sharma1 Nov 2020 11:15 AM IST"We are pleased with today's decision by the European Patent Office, which upholds the rigorous standard for pharmaceutical patents that we argued for...
Alirocumab reduces lipoprotein(a), lowers cardiovascular risk, finds study Dr Satabdi Saha24 Oct 2020 12:30 PM ISTAmong patients receiving intensive statin therapy following a recent acute coronary syndrome, patient-level reductions in lipoprotein(a) by...
Alirocumab cuts LDL cholesterol by 35% in familial hypercholesterolemia Hina Zahid4 April 2020 9:00 PM ISTThe cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous...
Alirocumab may cause scleritis with uveal effusion in susceptible patients Dr. Kamal Kant Kohli10 March 2020 1:00 PM ISTAlirocumab has been linked to scleritis with uveal effusion in patient with autoimmune diseases according to a case study. In the literature...
